Table of Content

Open Access iconOpen Access

ARTICLE

Examining the In Vitro Efficacy of the IAP Antagonist Birinapant as a Single Agent or in Combination With Dacarbazine to Induce Melanoma Cell Death

Vesna Vetma*†‡, Jan Rožanc§, Emilie M. Charles*†, Christian T. Hellwig*†‡¶, Leonidas G. Alexopoulos§#, Markus Rehm*†‡#

* Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland, Dublin 2, Ireland
† Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin 2, Ireland
‡ Institute of Cell Biology and Immunology, University of Stuttgart, Stuttgart, Germany
§ ProtATonce Ltd., Athens, Greece
¶ Stuttgart Research Center Systems Biology, University of Stuttgart, Stuttgart, Germany
# Department of Mechanical Engineering, National Technical University of Athens, Athens, Greece

Oncology Research 2017, 25(9), 1489-1494. https://doi.org/10.3727/096504017X14897145996933

Abstract

Antagonists of inhibitors of apoptosis proteins (IAPs), alone or in combination with genotoxic therapeutics, have been shown to efficiently induce cell death in various solid tumors. The IAP antagonist birinapant is currently being tested in phase II clinical trials. We herein aimed to investigate the antitumor efficacy of dacarbazine in vitro, both as a single agent and in combination with birinapant, in melanoma cell lines. Covering clinically relevant drug concentration ranges, we conducted a total of 5,400 measurements in a panel of 12 human melanoma cell lines representing different stages of disease progression. Surprisingly, functionally relevant synergies or response potentiation in combination treatments was not observed, and only one cell line modestly responded to birinapant single treatment (approximately 16% cell death). Although we did not study the underlying resistance mechanisms or more complex in vivo scenarios in which dacarbazine/birinapant response synergies may still possibly manifest, our findings are nevertheless noteworthy because IAP antagonists were demonstrated to strongly enhance responses to DNA-damaging agents in cell lines of other cancer types under comparable experimental conditions in vitro.

Keywords


Cite This Article

APA Style
Vetma, V., Rožanc, J., Charles, E.M., Hellwig, C.T., Alexopoulos, L.G. et al. (2017). Examining the in vitro efficacy of the IAP antagonist birinapant as a single agent or in combination with dacarbazine to induce melanoma cell death. Oncology Research, 25(9), 1489-1494. https://doi.org/10.3727/096504017X14897145996933
Vancouver Style
Vetma V, Rožanc J, Charles EM, Hellwig CT, Alexopoulos LG, Rehm M. Examining the in vitro efficacy of the IAP antagonist birinapant as a single agent or in combination with dacarbazine to induce melanoma cell death. Oncol Res. 2017;25(9):1489-1494 https://doi.org/10.3727/096504017X14897145996933
IEEE Style
V. Vetma, J. Rožanc, E.M. Charles, C.T. Hellwig, L.G. Alexopoulos, and M. Rehm "Examining the In Vitro Efficacy of the IAP Antagonist Birinapant as a Single Agent or in Combination With Dacarbazine to Induce Melanoma Cell Death," Oncol. Res., vol. 25, no. 9, pp. 1489-1494. 2017. https://doi.org/10.3727/096504017X14897145996933



cc This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • 36

    View

  • 23

    Download

  • 0

    Like

Share Link